Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants

Chia Chun Chiang, Todd J. Schwedt

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Calcitonin Gene-Related Peptide (CGRP) plays a pivotal role in migraine pathophysiology. Two types of CGRP function-blocking modalities, monoclonal antibodies, and small molecules (gepants), have been developed to target the CGRP ligands and CGRP receptors. Four CGRP monoclonal antibodies have received FDA approval for the prevention of migraine: erenumab, fremanezumab, galcanezumab, and eptinezumab. Two gepants have been approved by the FDA for the acute treatment of migraine: ubrogepant and rimegepant. Multiple clinical trials of the CGRP monoclonal antibodies and gepants, and now some open-label long-term extension data, established their efficacy, safety, and tolerability. In this chapter, we summarize the major clinical trials, pharmacokinetic insights, safety and tolerability profiles, and real-world data (if available) of the CGRP monoclonal antibodies and gepants.

Original languageEnglish (US)
Title of host publicationProgress in Brain Research
EditorsShuu-Jiun Wang, Shuu-Jiun Wang, Chi Ieong Lau, Chi Ieong Lau, Chi Ieong Lau, Chi Ieong Lau, Chi Ieong Lau
PublisherElsevier B.V.
Pages143-170
Number of pages28
ISBN (Print)9780128211083
DOIs
StatePublished - 2020

Publication series

NameProgress in Brain Research
Volume255
ISSN (Print)0079-6123
ISSN (Electronic)1875-7855

Keywords

  • CGRP monoclonal antibody
  • CGRP receptor
  • Calcitonin Gene-Related Peptide
  • Gepants
  • Migraine acute therapy
  • Migraine preventive therapy

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants'. Together they form a unique fingerprint.

Cite this